MabThera indications extended

The monoclonal antibody MabThera (rituximab) has received regulatory approval for two additional indications, rheumatoid arthritis and non-Hodgkin's lymphoma.

In rheumatoid arthritis, MabThera may be used in combination with methotrexate for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease modifying antirheumatic drugs including one or more tumour necrosis factor inhibitor therapies.
The efficacy of MabThera in alleviating the signs and symptoms of rheumatoid arthritis has been shown in three multicentre trials in which rituximab 2 x 1000mg significantly increased the proportion of patients achieving at least a 20% improvement in ACR (American College of Rheumatology) score compared with patients treated with methotrexate alone.

In non-Hodgkin's lymphoma, MabThera may be used as maintenance therapy in patients with relapsed/refractory follicular disease responding to induction therapy with chemotherapy with or without MabThera.

This licence extension was granted following the results of a trial in which patients who responded to induction treatment and who received MabThera maintenance treatment consisting of a single infusion of MabThera at 375mg/m2 every three months had significantly improved outcome in terms of disease progression, relapse and death compared with those in the control group.

Further information: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Herts AL7 1TW. Tel: (01707) 366000.


Read these next

Pixuvri: new option in the treatment of non-Hodgkin's B-cell lymphoma

Pixuvri: new option in the treatment of non-Hodgkin's B-cell lymphoma

Pixuvri (pixantrone) is indicated as monotherapy in...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases